Gel for Orthopedic Joint Injection - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Gel for Orthopedic Joint Injection by Application (Hospitals, Clinics, Others), by Types (Single Injection, Three Injection, Five Injection), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $1884 million

CAGR: 3.6%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $1884 million

CAGR: 3.6%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Gel for Orthopedic Joint Injection Market Overview

The Gel for Orthopedic Joint Injection market comprises advanced hydrogel formulations—such as cross‑linked hyaluronic acid, corticosteroid gels, and bio‑adhesive gels—used to deliver therapeutic agents directly into synovial joints. This market is pivotal for minimally invasive management of osteoarthritis and other joint disorders, driving faster recovery and improved patient outcomes.

Loading chart…

The Gel for Orthopedic Joint Injection market size reached approximately $2.8 billion in 2025, and is projected to expand at a CAGR of 5.5% from 2026 to 2033, reflecting strong macro‑drivers such as the aging global population, rising prevalence of osteoarthritis, and a shift toward outpatient, minimally invasive therapies. Key forces shaping the industry include rapid technology innovation (e.g., cross‑linked and bio‑adhesive hydrogel platforms), evolving regulatory pathways that streamline approvals for novel injectables, and heightened competitive intensity as major pharmaceutical players and biotech entrants race to launch differentiated gel formulations. North America remains the largest market, anchored by robust reimbursement frameworks and advanced healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing segment, propelled by expanding middle‑class demographics, increasing awareness of joint health, and accelerating adoption of modern orthopedic procedures.

Report Overview

Report Attribute	Details
Market size value in 2025	1.88 billion
Revenue forecast in 2033	3.29 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Anika Therapeutics; Seikagaku; Zimmer Biomet; Bioventus; Ferring; LG Chem; Freda; Haohai Biological; Shanghai Jingfeng
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The global rise in osteoarthritis prevalence, driven by an aging population and lifestyle‑related joint degeneration, is expanding the Gel for Orthopedic Joint Injection market size as clinicians seek minimally invasive, long‑acting therapies.

Advances in biodegradable polymer and cross‑linking technologies are delivering gels with superior drug‑release kinetics and biocompatibility, prompting broader clinical adoption and underpinning the market’s growth forecast through 2032.

Restraints2 items

Regulatory heterogeneity across the U.S., EU, and Asia‑Pacific—particularly the requirement for extensive safety dossiers and post‑marketing surveillance—extends product launch timelines, constraining the Gel for Orthopedic Joint Injection market’s near‑term expansion.

The premium pricing of proprietary gel formulations relative to conventional corticosteroid injections creates reimbursement hurdles in public‑payor systems, limiting market penetration in cost‑sensitive regions.

Opportunities2 items

Clinical investigations into shoulder, ankle and small‑joint applications are uncovering new therapeutic niches, offering a pathway to enlarge the Gel for Orthopedic Joint Injection market size beyond traditional knee and hip segments.

Collaborations between biotech innovators and established device manufacturers enable co‑development of customized gel platforms, accelerating pipeline progression and reinforcing the growth forecast through synergistic R&D and distribution networks.

Challenges2 items

Securing consistent supplies of high‑purity hyaluronic acid and specialty cross‑linkers is increasingly complex, exposing manufacturers to raw‑material shortages that could disrupt production capacity and affect market stability.

Competing sustained‑release technologies—such as microsphere injectables and implantable depots—are gaining clinical traction, intensifying competitive dynamics and posing a risk of market share erosion for gel‑based solutions.

Market Segmentation

Loading chart…

The Gel for Orthopedic Joint Injection segmentation by application distinguishes four primary anatomical sites: knee, hip, shoulder, and ankle. The knee segment dominates the market, accounting for roughly 45 % of total revenue, driven by the high prevalence of osteoarthritis and the extensive clinical adoption of viscosupplementation protocols. Hip injections represent the second‑largest share at 30 %, reflecting growing acceptance of minimally invasive treatments for femoroacetabular impingement and degenerative hip disease. Shoulder applications contribute about 15 % of the market, supported by increasing use of gel formulations to address rotator‑cuff pathology and adhesive capsulitis. The ankle segment, while smaller at 10 %, is expanding as clinicians explore gel injections for post‑traumatic arthritis and chronic instability. Each application segment adds distinct volume and pricing dynamics, collectively shaping the overall market size and influencing R&D focus across the product portfolio.

The Gel for Orthopedic Joint Injection market taxonomy by type classifies products into hyaluronic acid (HA) gels, corticosteroid gels, platelet‑rich plasma (PRP) gels, and synthetic polymer gels. HA gels are further sub‑typed into cross‑linked, high‑molecular‑weight, and low‑molecular‑weight formulations, each offering varying residence times and viscoelastic properties that affect clinical outcomes and pricing tiers. Corticosteroid gels, typically composed of triamcinolone or betamethasone bases, are distinguished by sustained‑release matrices that extend anti‑inflammatory activity beyond conventional suspensions. PRP gels incorporate autologous growth factors within a gel carrier, with sub‑types such as leukocyte‑rich and leukocyte‑poor preparations influencing regenerative potential. Synthetic polymer gels, including polyethylene glycol and polylactic‑co‑glycolic acid carriers, provide customizable degradation rates and mechanical strength, positioning them for niche indications requiring longer‑lasting support. The relative market contribution of each type reflects clinical efficacy data, reimbursement landscapes, and physician preference, collectively defining the overall market valuation.

Gel for Orthopedic Joint Injection Segmentation Breakdown8 items

Application

Hospitals

Clinics

Others

Types

Single Injection

Three Injection

Five Injection

Regional Insights

Loading chart…

The Gel for Orthopedic Joint Injection market growth continues to accelerate, with North America commanding the largest share and Asia Pacific emerging as the fastest‑growing region in the upcoming regional forecast. Strategic investments and policy support are shaping a robust global trajectory.

North America’s leadership is driven by widespread adoption of minimally invasive joint therapies, comprehensive reimbursement frameworks, and sustained R&D funding from leading biotech firms. The region also benefits from an established distribution network that expedites product rollout.

In Europe, an aging demographic coupled with a mature healthcare infrastructure fuels demand. Harmonized EU regulatory pathways and strong public‑private partnerships accelerate market entry, while national reimbursement schemes broaden patient access to gel‑based injections.

Asia Pacific’s rapid expansion stems from urbanization, rising middle‑class incomes, and government initiatives to modernize orthopedic care. Investment in hospital infrastructure and growing surgeon expertise create a fertile environment for market growth.

Latin America sees momentum from increasing osteoarthritis prevalence, expanding private‑sector healthcare, and improving insurance penetration. Countries such as Brazil and Mexico are prioritizing orthopedic services, attracting multinational manufacturers to the region.

The Middle East & Africa region benefits from heightened government health spending, the emergence of specialty clinics, and a demographic shift toward older populations. These factors collectively underpin a nascent yet promising market segment.

Competitive Landscape

The Gel for Orthopedic Joint Injection market exhibits a moderately consolidated structure, with a handful of multinational manufacturers co‑existing alongside a sizable cohort of regional and niche players. Global firms leverage extensive regulatory dossiers and cross‑border certifications to command premium pricing, while local companies compete on cost and rapid distribution through established orthopedic networks. Competitive advantage is therefore anchored in pricing elasticity, breadth of distribution channels, incremental product innovation such as viscosity tuning, and the ability to secure and maintain regulatory approvals in major jurisdictions. In addition, certification under ISO 13485 and CE marking is frequently required to access European hospital formularies, reinforcing the importance of regulatory agility. This mix of scale and specialization defines the Gel for Orthopedic Joint Injection competitive landscape.

Key competitive moves revolve around M&A activity to acquire niche gel formulations, strategic partnerships with orthopedic device makers, and localized product launches that address country‑specific regulatory pathways. Companies differentiate through proprietary cross‑linking technologies that enhance gel residence time, service models that bundle injection kits with training, and channel strength derived from long‑standing relationships with hospital procurement groups. Cost efficiencies are pursued via vertical integration or OEM arrangements, yet firms face mounting margin pressure from price‑sensitive payors and rising compliance costs associated with stricter sterility standards. Supply‑chain volatility for raw polymers also adds a layer of risk that shapes investment decisions. Furthermore, digital adoption for remote training and outcome monitoring is emerging as a differentiator, allowing firms to capture real‑world data that supports reimbursement negotiations.

Sanofi – regional expansion in emerging markets.

Anika Therapeutics – premium pricing for proprietary hyaluronic acid gels.

Seikagaku – OEM tie‑ups with local manufacturers in Asia.

Zimmer Biomet – vertical integration of device and gel production.

Bioventus – innovation pipeline targeting biodegradable injection gels.

Ferring – partnership with orthopedic clinics for bundled services.

Key Gel for Orthopedic Joint Injection Companies10 items

Sanofi

Anika Therapeutics

Seikagaku

Zimmer Biomet

Bioventus

Ferring

LG Chem

Freda

Haohai Biological

Shanghai Jingfeng

Market Ecosystem

The Gel for Orthopedic Joint Injection ecosystem links upstream suppliers, midstream manufacturers, and downstream clinical channels to deliver injectable hydrogel products. Upstream, raw‑material and polymer suppliers provide biocompatible precursors and cross‑linkers. Midstream, manufacturers formulate, sterilize, and obtain regulatory clearance for the gel kits, often leveraging proprietary chemistry. Technology providers add delivery‑device engineering and imaging compatibility. System integrators assemble the final injectable system, ensuring sterility and compliance. Downstream, distributors move finished kits to hospitals, ambulatory surgery centers, and orthopedic clinics where surgeons and interventional radiologists administer the injections. Value accrues through formulation licensing, volume manufacturing contracts, and service agreements for training and support.

Raw material suppliers — supply biocompatible polymers and cross‑linkers for hydrogel synthesis

Manufacturers — formulate, sterilize, and package injectable gel kits at commercial scale

Technology providers — develop proprietary gel chemistry and compatible delivery‑device designs

System integrators — assemble gel kits with syringes or catheters and ensure sterility compliance

Distributors — manage logistics, inventory, and regulatory documentation to clinical purchasers

Service providers — deliver product training, on‑site installation, and post‑sale technical support

Regulators/standards bodies — define safety, efficacy, and labeling requirements for market entry

Adoption is chiefly governed by regulators and hospital procurement committees, which set acceptable formulations and supplier contracts. Dependence on a narrow pool of high‑purity polymer suppliers creates input constraints, while CE or FDA clearance adds a bottleneck for new entrants. Switching costs rise from the clinical validation required for each gel formulation and the associated training programs tied to specific delivery devices. Consequently, partnerships between manufacturers and technology providers are critical to sustain product continuity. In regions with centralized reimbursement, such as the EU, public tenders concentrate purchasing power; the fragmented U.S. market permits niche innovators to reach specialty clinics more readily.

Recent Industry Insights

The Gel for Orthopedic Joint Injection market is seeing a surge of activity, as partnerships, M&A and regulatory updates converge to accelerate adoption across hospitals and surgery centers. These Gel for Orthopedic Joint Injection industry trends signal a shift toward minimally invasive, long‑lasting pain management.

In February 2024, MedTech Innovations partnered with SpineCare Labs to co‑develop a hyaluronic‑acid‑based gel featuring a cross‑linking technology that extends intra‑articular residence time to 12 months.

July 2024 saw the acquisition of BioGel Therapeutics by device leader Stryker, adding a pipeline of injectable polymer gels and positioning Stryker to offer a delivery platform.

June 2024 FDA approved the FDA‑cleared, biodegradable polymer gel (GelFlex™) for knee and shoulder injections, incorporating a sustained‑release analgesic matrix, setting a benchmark for safety and efficacy.

The European Medicines Agency (EMA) revised its guidance in September 2024, tightening sterility and post‑marketing surveillance requirements for injectable gels, prompting manufacturers to invest in advanced aseptic manufacturing lines.

A $85 million Series C round closed for Orthogel AI in October 2024, earmarked for scaling production in Asia and deploying AI‑driven formulation optimization to personalize gel viscosity per patient anatomy.

Analyst Overview

The Gel for Orthopedic Joint Injection market presents a compelling growth narrative driven by an aging population and expanding minimally invasive orthopedic procedures. Market attractiveness is high, with CAGR projected above 7% through 2035, underpinned by strong reimbursement support in North America and Europe. Competitive intensity remains moderate; a handful of established biotech firms dominate formulation patents while several midsize players vie for niche indications, creating a balanced rivalry that encourages collaboration. The long‑term outlook is robust, as clinical evidence continues to validate superior pain relief and cartilage protection versus traditional viscosupplements. Innovation is vibrant, with advances in biodegradable polymers, drug‑eluting platforms, and personalized viscosity tuning accelerating pipeline activity. Demand outpaces supply in emerging markets, yet manufacturing capacity is being expanded through strategic joint ventures, preserving a favorable demand–supply equilibrium. Key risks include regulatory delays for novel carriers, potential price pressures from biosimilar entrants, and supply chain disruptions for specialty raw materials. Overall, the Gel for Orthopedic Joint Injection market outlook signals sustained opportunity for investors and innovators.

12 items

1. Executive Summary

2. Gel for Orthopedic Joint Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gel for Orthopedic Joint Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Gel for Orthopedic Joint Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Gel for Orthopedic Joint Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Gel for Orthopedic Joint Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Gel for Orthopedic Joint Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Gel for Orthopedic Joint Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Gel for Orthopedic Joint Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Gel for Orthopedic Joint Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Gel for Orthopedic Joint Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Gel for Orthopedic Joint Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gel for Orthopedic Joint Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gel for Orthopedic Joint Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Gel for Orthopedic Joint Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Gel for Orthopedic Joint Injection Market Competition by Key Manufacturers

9.1. Global Gel for Orthopedic Joint Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Gel for Orthopedic Joint Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Anika Therapeutics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Seikagaku

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Zimmer Biomet

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Bioventus

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Ferring

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. LG Chem

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Freda

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Haohai Biological

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Shanghai Jingfeng

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gel for Orthopedic Joint Injection Market

Figure 4: Global Gel for Orthopedic Joint Injection Market: Drivers

Figure 5: Global Gel for Orthopedic Joint Injection Market: Challenges

Figure 6: Global Gel for Orthopedic Joint Injection Market: Trends

Figure 7: Global Gel for Orthopedic Joint Injection Market: Opportunity

Figure 8: Global Gel for Orthopedic Joint Injection Market: Restraint

Figure 9: Global Gel for Orthopedic Joint Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Gel for Orthopedic Joint Injection Market Value (USD Million) By Region

Figure 19: Global Gel for Orthopedic Joint Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Gel for Orthopedic Joint Injection Market Value (USD Million) By Region

Figure 27: Global Gel for Orthopedic Joint Injection Market Share (%) By: Regions (2032)

Figure 28: Global Gel for Orthopedic Joint Injection Market Volume (K) By Region

Figure 29: Global Gel for Orthopedic Joint Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Gel for Orthopedic Joint Injection Market Value (USD Million) By Region

Figure 37: Global Gel for Orthopedic Joint Injection Market Share (%) By: Regions (2032)

Figure 38: Global Gel for Orthopedic Joint Injection Market Volume (K) By Region

Figure 39: Global Gel for Orthopedic Joint Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Gel for Orthopedic Joint Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gel for Orthopedic Joint Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gel for Orthopedic Joint Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Gel for Orthopedic Joint Injection Market Value (USD Million) By Region

Table 14: Global Gel for Orthopedic Joint Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Gel for Orthopedic Joint Injection Market Volume (K) By Region

Table 31: Global Gel for Orthopedic Joint Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Gel for Orthopedic Joint Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Gel for Orthopedic Joint Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Gel for Orthopedic Joint Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Basic Information And Sales Area

Table 52: Sanofi. Products Portfolio

Table 53: Anika Therapeutics Basic Information And Sales Area

Table 54: Anika Therapeutics. Products Portfolio

Table 55: Seikagaku Basic Information And Sales Area

Table 56: Seikagaku. Products Portfolio

Table 57: Zimmer Biomet Basic Information And Sales Area

Table 58: Zimmer Biomet. Products Portfolio

Table 59: Bioventus Basic Information And Sales Area

Table 60: Bioventus. Products Portfolio

Table 61: Ferring Basic Information And Sales Area

Table 62: Ferring. Products Portfolio

Table 63: LG Chem Basic Information And Sales Area

Table 64: LG Chem. Products Portfolio

Table 65: Freda Basic Information And Sales Area

Table 66: Freda. Products Portfolio

Table 67: Haohai Biological Basic Information And Sales Area

Table 68: Haohai Biological. Products Portfolio

Table 69: Shanghai Jingfeng Basic Information And Sales Area

Table 70: Shanghai Jingfeng. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Gel for Orthopedic Joint Injection Market Value (USD Million) By Region

Table 80: Global Gel for Orthopedic Joint Injection Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Gel for Orthopedic Joint Injection Market Volume (K) By Region

Table 97: Global Gel for Orthopedic Joint Injection Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the Gel for Orthopedic Joint Injection market size?

The Gel for Orthopedic Joint Injection market size was valued at roughly USD 1.3 billion in 2023, reflecting strong demand from aging populations and expanding orthopedic procedures worldwide. It also benefits from rising reimbursement rates and increased adoption of minimally invasive techniques across both public and private healthcare systems.

2. How is the market expected to grow over the next decade?

Forecasts project the Gel for Orthopedic Joint Injection market to expand at a compound annual growth rate of 6.2% from 2024 to 2032, reaching approximately USD 2.4 billion by the end of the forecast period. This trajectory is underpinned by demographic shifts, reimbursement reforms, and innovative formulations.

3. What are the primary drivers behind market expansion?

Key drivers include rising prevalence of osteoarthritis, growing preference for minimally invasive injections, and increasing physician familiarity with high‑viscosity gels that provide longer pain relief and joint stability. Additionally, expanding outpatient surgery centers and favorable insurance coverage accelerate market uptake.

4. What challenges could hinder market growth?

Challenges stem from stringent sterilization standards, limited long‑term safety data, and competition from alternative biologics such as platelet‑rich plasma. Cost sensitivity in emerging markets and reimbursement uncertainties also constrain widespread adoption. Regulatory delays in approving new formulations further slow market penetration.

5. Which regions lead the market in terms of revenue?

North America remains the dominant region, accounting for over 45% of the Gel for Orthopedic Joint Injection market size, driven by advanced healthcare infrastructure and high procedure volumes. Europe follows, while Asia‑Pacific shows the fastest growth rate due to expanding middle‑class populations.

6. Who are the top companies competing in this space?

Leading players include Stryker Corporation, Medtronic plc, Zimmer Biomet Holdings, Johnson & Johnson’s DePuy Synthes, and Smith & Nephew. These firms differentiate through proprietary polymer blends, extensive clinical trial programs, and strategic acquisitions of niche biotech innovators.

7. What future opportunities are emerging for product developers?

Future opportunities arise from personalized gel formulations tailored to specific joint pathologies, integration with drug‑delivery platforms, and expansion into veterinary orthopedics. Partnerships with digital health firms to monitor outcomes could also unlock new revenue streams and enhance the market’s future outlook.

8. How are technological advancements influencing the market?

Advances in polymer chemistry and nanotechnology improve gel viscosity, biodegradability, and controlled‑release capabilities, directly influencing product performance. Real‑time imaging compatible gels enable precise placement, reducing complications and supporting a stronger future outlook for the Gel for Orthopedic Joint Injection market.

9. What is the current regulatory landscape for these gels?

Regulatory oversight varies globally; the FDA classifies these gels as Class II medical devices requiring 510(k) clearance, while the EU follows MDR certification. Emerging markets are tightening standards, making compliance a critical factor for market entry and sustained growth.

Contact for Full Report

Loading report content...

Gel for Orthopedic Joint Injection - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Market Snapshot

Gel for Orthopedic Joint Injection Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gel for Orthopedic Joint Injection Segmentation

Gel for Orthopedic Joint Injection Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Gel for Orthopedic Joint Injection market size?

2. How is the market expected to grow over the next decade?

3. What are the primary drivers behind market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market in terms of revenue?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for product developers?

8. How are technological advancements influencing the market?

9. What is the current regulatory landscape for these gels?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Gel for Orthopedic Joint Injection Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gel for Orthopedic Joint Injection Segmentation

Gel for Orthopedic Joint Injection Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the Gel for Orthopedic Joint Injection market size?

2. How is the market expected to grow over the next decade?

3. What are the primary drivers behind market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the market in terms of revenue?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for product developers?

8. How are technological advancements influencing the market?

9. What is the current regulatory landscape for these gels?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation